2. Search Result
Search Result
Results for "

periodontal+disease

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

2

Biochemical Assay Reagents

5

Peptides

5

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N8440
    Gibberellin A4

    		NF-κB Infection
    Gibberellin A4 is a type of bioactive gibberellin. Gibberellin A4 promotes flowering in apple trees. Gibberellin A4 also exhibits anti-NF-κB and antioxidant activities. Gibberellin A4 can be used in the research of periodontal diseases .
    Gibberellin A4
  • HY-P4744
    LL-37 amide
    2 Publications Verification

    		 Formyl Peptide Receptor (FPR) Bacterial Infection Cancer
    LL-37 amide is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED99=8.5-8.7 μg/mL). LL-37 amide exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .
    LL-37 amide
  • HY-32350
    Ercalcitriol
    3 Publications Verification

    1α,25-Dihydroxy Vitamin D2

    		 VD/VDR Drug Metabolite Endogenous Metabolite Metabolic Disease
    Ercalcitriol (1α,25-Dihydroxy Vitamin D2) is a vitamin D receptor (VDR) agonist with high binding affinity. After binding to VDR, Ercalcitriol forms a complex with retinoid X receptor (RXR) to regulate target gene transcription. For example, Ercalcitriol induces human gingival/oral epithelial cells to produce human cat antimicrobial peptide (hCAP-18/LL-37), which has antimicrobial activity against periodontal pathogens such as Porphyromonas gingivalis. Ercalcitriol enhances the innate immune defense of the oral mucosa by promoting the expression of antimicrobial peptides, and is mainly used in the study of periodontal diseases and immune-related oral diseases .
    Ercalcitriol
  • HY-D1056D
    Lipopolysaccharides, from P. gingivalis
    3 Publications Verification

    LPS, from Porphyromonas gingivalis

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from P. gingivalis (LPS, from Porphyromonas gingivalis) are endotoxins and TLR4 activators extracted from Porphyromonas gingivalis (P. gingivalis) and are classified as S (smooth) type LPS. Lipopolysaccharides, from P. gingivalis possess the typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from P. gingivalis activate TLR-4 in immune cells and are important virulence factors in the mechanism of periodontal disease. Lipopolysaccharides, from P. gingivalis can be used in research related to periodontitis .
    It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
    Lipopolysaccharides, from P. gingivalis
  • HY-150205
    Succinate/succinate receptor antagonist 1

    		Succinate Receptor 1 Inflammation/Immunology
    Succinate/succinate receptor antagonist 1 is an antagonist of the succinate/succinate receptor. Succinate/succinate receptor antagonist 1 can inhibit the activation of succinate receptor 1 (SUCNR1). Succinate/succinate receptor antagonist 1 can block succinate signaling. Succinate/succinate receptor antagonist 1 can be used for the study of periodontal disease .
    Succinate/succinate receptor antagonist 1
  • HY-P4744A
    LL-37 amide TFA
    2 Publications Verification

    		 Formyl Peptide Receptor (FPR) Bacterial Infection Cancer
    LL-37 amide TFA is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED99=8.5-8.7 μg/mL). LL-37 amide TFA exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide TFA possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .
    LL-37 amide TFA
  • HY-10979
    AN0128

    		Bacterial Infection Inflammation/Immunology
    AN0128 is a boron-containing antibacterial and anti-inflammatory agent. AN0128 against S. aureus, S. epidermidis, P. acnes, B. subtilis with minimum inhibitory concentration (MIC) values of 1, 0.5, 0.3, 1 μg/mL. AN0128 can be used for the research of periodontal disease and cutaneous diseases .
    AN0128
  • HY-N3341
    Macrocarpal H

    		Glucosylceramide Synthase (GCS) Bacterial Infection
    Macrocarpal H is a natural compound that can be isolated from the Leaves of Eucalyptus globulus. Macrocarpal H exhibits antibacterial activity against Gram-positive cariogenic bacteria and Gram-negative periodontopathic bacteria. Macrocarpal H inhibits adherent water-insoluble glucan synthesis via glucosyltransferase. Macrocarpal H can be used for the research of caries, periodontal disease, dental caries, periodontal disorders .
    Macrocarpal H
  • HY-N0946
    (-)-Pinoresinol 4-O-glucoside

    (-)-Pinoresinol 4-O-β-D-glucopyranoside

    		 Glycosidase Metabolic Disease
    (-)-Pinoresinol 4-O-glucoside ((-)-Pinoresinol 4-O-β-D-glucopyranoside) is a potent and orally active α-glucosidase inhibitor with an IC50 value of 48.13 µM. (-)-Pinoresinol 4-O-glucoside increases cell migration and early differentiation of pre-osteoblasts. (-)-Pinoresinol 4-O-glucoside increases protein level of BMP2, p-Smad1/5/8, RUNX2. (-)-Pinoresinol 4-O-glucoside attenuates oxidative stress, hyperglycemia and hepatic toxicity. (-)-Pinoresinol 4-O-glucoside has the potential for the research of osteoporosis and periodontal disease .
    (-)-Pinoresinol 4-O-glucoside
  • HY-N3345
    Macrocarpal B

    		Bacterial Infection
    Macrocarpal B is an antibacterial compounds. Macrocarpal B can be isolated from the branch of Eucalyptus globulus. Macrocarpal B can be used for the research of periodontal disease .
    Macrocarpal B
  • HY-Y0332L
    Potassium dihydrogen phosphate, meets analytical specification of Ph. Eur., NF, E340

    Potassium phosphate monobasic, meets analytical specification of Ph. Eur., NF, E340

    		 Biochemical Assay Reagents NF-κB Others
    Potassium dihydrogen phosphate (Potassium phosphate monobasic), meeting the analytical specifications of Ph. Eur., NF, E340, is a reagent with buffering capacity, used for preparing biological buffers. Potassium dihydrogen phosphate downregulates the expression of IκBα in the cytoplasm, increases the expression of p-P65 in the cytoplasm, and upregulates the expression of P65 in the nucleus, thereby activating the NF-κB pathway. Potassium dihydrogen phosphate promotes the proliferation of human periodontal ligament stem cells in the logarithmic growth phase. Potassium dihydrogen phosphate upregulates the expression of odontogenic/osteogenic markers (OCN, DSP/DSPP, OSX, RUNX2, ALP) in human periodontal ligament stem cells and enhances the mineralization capacity of these cells. Potassium dihydrogen phosphate can be used in the research of periodontal diseases .
    Potassium dihydrogen phosphate, meets analytical specification of Ph. Eur., NF, E340
  • HY-N12240
    Oleanolic aldehyde

    		Bacterial Infection
    Oleanolic aldehyde is an antimicrobial compound used to inhibit oral bacteria. Oleanolic aldehyde inhibits Streptococcus mutans and Porphyromonas gingivalis, which are associated with dental caries and periodontal disease, with minimum inhibitory concentrations (MICs) of 488 μg/mL and 250 μg/mL, respectively .
    Oleanolic aldehyde
  • HY-P3567
    (p-Iodo-Phe7)-ACTH (4-10)

    		Melanocortin Receptor Neurological Disease
    (p-Iodo-Phe7)-ACTH (4-10) is a adrenocorticotrophic hormone (ACTH) derivative, which is produced and secreted by the anterior pituitary gland. (p-Iodo-Phe7)-ACTH (4-10) serves as a melanocortin (MC) receptor antagonist and inhibits α-melanocyte-stimulating hormone (α-MSH)-induced excessive grooming behavior in rats .
    (p-Iodo-Phe7)-ACTH (4-10)
  • HY-P2434
    AP102

    		Somatostatin Receptor Neurological Disease Metabolic Disease Cancer
    AP102 is a dual SSTR2/SSTR5-specific somatostatin analog (SSA). AP102 is a disulfide-bridged octapeptide SSA containing synthetic iodinated amino acids. AP102 binds with subnanomolar affinity to SSTR2 and SSTR5 (IC50: 0.63 and 0.65 nM, respectively). AP102 does not bind to SSTR1 or SSTR3. AP102 can be used for acromegaly and neuroendocrine tumors research .
    AP102
  • HY-B0746
    Flurbiprofen sodium

    dl-Flurbiprofen sodium

    		 Endogenous Metabolite Inflammation/Immunology
    Flurbiprofen sodium (dl-Flurbiprofen sodium) is a nonsteroidal anti-inflammatory agent (NSAID) with anti-inflammatory and analgesic activities. Flurbiprofen sodium is used to reduce bone resorption in periodontal disease, and it works by inhibiting carbonic anhydrase. Flurbiprofen sodium is formulated as biodegradable microspheres for use as a compound delivery system, particularly within the periodontal pocket. The release rate of flurbiprofen sodium is related to the concentration of polymer and polyvinyl alcohol used in its preparation .
    Flurbiprofen sodium
  • HY-123429
    CK0683A

    		Antibiotic Infection
    CK0683A is a novel biaminourea antibiotic with antiplaque effects and demonstrated efficacy in experimental mouse dental disease models. A 12-week study in beagles compared its efficacy in terms of plaque and gingivitis reduction, staining potential, and safety. Dogs were selected as the study subjects because the onset and progression of canine periodontal disease is similar to that of humans. As a positive control for plaque and gingivitis reduction and staining, chlorhexidine acetate was selected because it is effective in both humans and dogs.
    CK0683A
  • HY-164036R
    Lolamicin (Standard)

    		Reference Standards Antibiotic Bacterial Infection
    Flurbiprofen (sodium) (Standard) is the analytical standard of Flurbiprofen (sodium). This product is intended for research and analytical applications. Flurbiprofen sodium (dl-Flurbiprofen sodium) is a nonsteroidal anti-inflammatory agent (NSAID) with anti-inflammatory and analgesic activities. Flurbiprofen sodium is used to reduce bone resorption in periodontal disease, and it works by inhibiting carbonic anhydrase. Flurbiprofen sodium is formulated as biodegradable microspheres for use as a compound delivery system, particularly within the periodontal pocket. The release rate of flurbiprofen sodium is related to the concentration of polymer and polyvinyl alcohol used in its preparation .
    Lolamicin (Standard)
  • HY-123479
    CK0492B

    		Antibiotic Infection
    CK0492B is a novel biaminourea antibiotic that has antiplaque properties in vitro and has shown efficacy in an experimental mouse dental disease model. A 12-week study in beagles compared its efficacy in reducing plaque and gingivitis, staining potential, and safety. Dogs were selected as the study subjects because the onset and progression of canine periodontal disease are similar to humans. Chlorhexidine acetate was selected as a positive control for plaque and gingivitis reduction and staining because it is effective in both humans and dogs.
    CK0492B
  • HY-32350S1
    Ercalcitriol-d3

    1α,25-Dihydroxy Vitamin D2-d3

    		 Isotope-Labeled Compounds Endogenous Metabolite VD/VDR Metabolic Disease
    Ercalcitriol-d3 (1α,25-Dihydroxy Vitamin D2-d3) is the deuterium labeled Ercalcitriol (HY-32350). Ercalcitriol (1α,25-Dihydroxy Vitamin D2) is a vitamin D receptor (VDR) agonist with high binding affinity. After binding to VDR, Ercalcitriol forms a complex with retinoid X receptor (RXR) to regulate target gene transcription. For example, Ercalcitriol induces human gingival/oral epithelial cells to produce human cat antimicrobial peptide (hCAP-18/LL-37), which has antimicrobial activity against periodontal pathogens such as Porphyromonas gingivalis. Ercalcitriol enhances the innate immune defense of the oral mucosa by promoting the expression of antimicrobial peptides, and is mainly used in the study of periodontal diseases and immune-related oral diseases .
    Ercalcitriol-d3
  • HY-P11767
    NCR247

    		Ferroptosis Parasite Infection
    NCR247 is a defensin-like nodule cysteine-rich (NCR) peptide and heme chelator. NCR247 induces iron starvation responses in Sinorhizobium meliloti and Medicago truncatula, and supports nitrogenase activity. NCR247 can be used in research related to periodontal disease and toxoplasmosis .
    NCR247
  • HY-B0746R
    Flurbiprofen sodium (Standard)

    dl-Flurbiprofen sodium (Standard)

    		 Endogenous Metabolite Reference Standards Inflammation/Immunology
    Flurbiprofen (sodium) (Standard) is the analytical standard of Flurbiprofen (sodium). This product is intended for research and analytical applications. Flurbiprofen sodium (dl-Flurbiprofen sodium) is a nonsteroidal anti-inflammatory agent (NSAID) with anti-inflammatory and analgesic activities. Flurbiprofen sodium is used to reduce bone resorption in periodontal disease, and it works by inhibiting carbonic anhydrase. Flurbiprofen sodium is formulated as biodegradable microspheres for use as a compound delivery system, particularly within the periodontal pocket. The release rate of flurbiprofen sodium is related to the concentration of polymer and polyvinyl alcohol used in its preparation .
    Flurbiprofen sodium (Standard)
  • HY-182757
    Y1693

    		RANKL/RANK Nuclear Factor of activated T Cells (NFAT) Cathepsin Metabolic Disease Inflammation/Immunology
    Y1693 is an orally active RANKL inhibitor with a Kd of 5.03 μM for hRANKL. Y1693 inhibits the activation of the downstream c-fos/NFATc1 signaling pathway by blocking its interaction with RANK. Y1693 significantly inhibits RANKL-induced osteoclast differentiation, F-actin ring formation and bone resorptive activity, while downregulating the mRNA and protein expressions of TRAP, cathepsin K, c-fos and NFATc1. Y1693 shows no obvious cytotoxicity to bone marrow-derived macrophages and osteoclast precursor cells, and exhibits favorable ADME properties. Y1693 improves ovariectomy-induced osteoporosis in mice and reverses ligation-induced periodontal alveolar bone loss. Y1693 is applicable to research related to osteoporosis and periodontal diseases .
    Y1693

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: